Teva optimistic U.S. top court to rule in favor of MS drug patent
TEL AVIV (Reuters) - Teva Pharmaceutical Industries is optimistic the U.S. Supreme Court will decide in its favor regarding patent protection for Copaxone, its multiple sclerosis treatment, Chief Executive Erez Vigodman said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - October 30, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Beta-Interferon, Glatiramer Acetate Cost-Effective in MSBeta-Interferon, Glatiramer Acetate Cost-Effective in MS
A new analysis from the UK has suggested that both beta-interferon and glatiramer acetate delay disability and are cost-effective for the long-term treatment of multiple sclerosis. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 19, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
ACTRIMS/ECTRIMS Summary
A review of some of the research from the recent ACTRIMS/ECTRIMSconference, including daclizumab, generic glatiramer acetate, a fingolimod similar, body temperature, cholesterol, comorbidities, stem cells, cognition, genetics, vitamin D and diet.
National MS Society (USA)
Latest MS research updates (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - September 16, 2014 Category: Neurology Source Type: news
Generic GA Shows Equivalence on MRI Endpoints in MSGeneric GA Shows Equivalence on MRI Endpoints in MS
A generic version of the MS drug glatiramer acetate looked similar to the branded product (Copaxone) in terms of reduction in MRI lesions and side effects in the GATE study. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 13, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Generic Copaxone for MS Passes Clinical Test
BOSTON (MedPage Today) -- A copycat version of the multiple sclerosis drug Copaxone, known generically as glatiramer acetate, performed similarly to the original product in a head-to-head trial, paving the way for it to win regulatory approval as a generic drug. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - September 12, 2014 Category: Journals (General) Source Type: news
Glatiramer acetate (Copaxone) side effects
A study shows that the new three times a week version of Copaxone caused about half the number of injection site reactions than the daily version. Reported at the ACTRIMS/ECTRIMS conference.
Teva press release
Glatiramer acetate (Copaxone) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - September 10, 2014 Category: Neurology Source Type: news
Natco Pharma's partner Mylan Inc files ANDA for generic Copaxone
According to IMS health, Copaxone 40 mg/mL had US sales of nearly USD 411.5 million for the 12 months ending June 30, 2014, it added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 30, 2014 Category: Pharmaceuticals Source Type: news
Teva Plans to Sue Dr. Reddy's Over Copaxone Patent Infringement
The filing of the lawsuit will trigger a 30-month stay of FDA approval of Dr. Reddy’s ANDA (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 12, 2014 Category: Pharmaceuticals Source Type: news
Teva may move court against Dr Reddy's for patent infringement
The Israeli drug maker already is involved in various legal battles with other drug firms over the patent litigations of Copaxone. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 11, 2014 Category: Pharmaceuticals Source Type: news
FDA's Looming Decision On A Generic To Teva's Copaxone Reveals Drug Approval Woes
A year ago, the Food and Drug Administration quietly posted a public notice that it wanted to hire an independent lab to test a generic drug that it had already approved. FDA wanted to make sure the drug was safe and effective. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 7, 2014 Category: Pharmaceuticals Authors: Scott Gottlieb Source Type: news
Fingolimod (Gilenya) eligibility extended by NHS England
Fingolimod can now be prescribed on the NHS in England for people who continue to have relapses despite taking beta interferon or glatiramer acetate and for people taking natalizumab who are at high risk of developing progressive multifocal leukoencephalopathy (PML). (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - July 1, 2014 Category: Neurology Source Type: news
Teva Loses Generic Copaxone Lawsuit Against FDA
Teva makes a move to block rivals including Mylan Inc. and Novartis AG’s Sandoz unit from making a less expensive generic drug (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 16, 2014 Category: Pharmaceuticals Source Type: news
Mylan Applauds Court's Ruling Dismissing Teva's Suit Against FDA on Copaxone(R)
PITTSBURGH, May 15, 2014 -- (Healthcare Sales & Marketing Network) -- Mylan Inc. (MYL) today commented on the ruling by the U.S. District Court for the District of Columbia against Teva in their suit against the U.S. Food and Drug Administration (FDA), wh... Biopharmaceuticals, Generics, FDA, LitigationMylan, Teva Pharmaceutical, Copaxone (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 15, 2014 Category: Pharmaceuticals Source Type: news
U.S. court dismisses Teva case to block copies of Copaxone
(Reuters) - A U.S. district court dismissed a case by Teva Pharmaceutical Industries Ltd against the U.S. Food and Drug Administration, part of the Israeli company's broad legal battle aimed at stopping generic versions of its Copaxone drug for multiple sclerosis. (Source: Reuters: Health)
Source: Reuters: Health - May 15, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
AAN round up
Brief collection of some of the topics covered at the recent American Academy of Neurology (AAN) conference. Includes Peginterferon beta-1a (Plegridy), estriol combined with Copaxone, whipworm eggs, ofatumumab, factors affecting, toxic B cells, diet, constraint-induced movement therapy, cognition in children, magnetic stimulation for depression, and salsa for improvements in balance.
National MS Society (USA)
Latest MS research updates (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - May 13, 2014 Category: Neurology Source Type: news
